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compliance for these days exceeded 90%. Evidence for
back and forward filling of paper diary cards was ob-
served. For the compliance-enhanced electronic diary, the
actual compliance rate was 93%.
CONCLUSIONS: Data from paper-based diaries are of
questionable validity, given that many of their entries are
not completed as required by the protocol. Science-based
electronic diaries can produce high rates of patient com-
pliance in the field. Improved methods for data collection
should encourage researchers in the pharmaceutical in-
dustry to aggressively evaluate electronic PRO (ePRO)
data to help differentiate their products.
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OBJECTIVE: Increasingly, federal authorities are request-
ing power calculations for secondary endpoints in clinical
trials, including patient reported outcomes (PRO). How-
ever, most PRO measures do not provide power calcula-
tions in their manuals; if provided, they are often based on
mixed samples of males and females. It is well docu-
mented that female and male PRO scores often differ.
Thus when designing women’s health trials, it may be
worthwhile to conduct power calculations using women’s
PRO scores and standard deviations. This study presents
the power and sample-size calculations for a variety of
questionnaires used in women’s health studies.
METHODS: The Menopause Quality of Life question-
naire (MENQOL), Women’s Health Questionnaire (WHQ),
Psychological General Well-Being Index (PGWB), and
Short Form 36 and 12 (SF-36/SF-12) were assessed. Pub-
lished information on scores and standard deviations in
female populations were used to determine sample sizes
needed to detect differences between two experimental
groups, post-intervention.
RESULTS: Results varied by questionnaire, due in part to
varying score ranges across questionnaires. For example, to
achieve 90% power with a ten-point difference the follow-
ing sample sizes per treatment arm were required: 158
women when using the MENQOL vasomotor score (range:
0–100); 47 women when using the WHQ total score (range:
0–102); 70 women when using the PGWB total score
(range: 22–132); 24 and 21 women when using the SF-36
and SF-12 Physical Component Summary (no floor/ceiling).
CONCLUSION: When calculating sample sizes, it is nec-
essary to keep in mind the questionnaire’s possible score
range in order to ensure that the power calculation is
based on a clinically meaningful difference between treat-
ment groups. These results may be used to help calculate
sample sizes needed to achieve sufficient power to detect
statistically significant differences in women’s health tri-
als for these widely used measures.
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OBJECTIVES: The availability of reliable methods for im-
puting hospital costs (e.g., relative values from the U.S. diag-
nosis-related group (DRG) payment system, cost weights
and average length of stay (LOS) estimates from the Austra-
lian refined DRG system, or average LOS from the French
Patient Homogeneous Groups), allows one to address two
design questions related to the collection of hospital unit
cost data for use in multinational clinical trials with eco-
nomic endpoints: 1) In individual countries, for how many
types of hospitalization should estimates be obtained? 2)
For how many countries should they be obtained?
METHODS: We addressed these questions by assuming
that unit cost estimates for 47 types of hospitalization
collected in four western European countries represented
the universe of hospitalizations. This assumption pro-
vided a population estimate against which we could mea-
sure the error associated with imputations in samples
drawn from the population. To answer the first question,
we: 1) randomly sampled subsets of hospitalization types
from this population and used them to develop imputa-
tion regressions; 2) used the results of the regressions to
impute costs from the remaining hospitalization types,
and 3) estimated measures of imputation error within
each sample. To answer the second question, we per-
formed a similar analysis, but instead sampled countries.
RESULTS: We found that the imputation error decreased
as the number of types of hospitalization and countries
sampled increased, but that the rate of reduction in error
shrank. We also found that error was minimized by ob-
taining estimates for fewer types of hospitalization from
more countries than the reverse.
CONCLUSION: The availability of reliable methods for
imputing hospitalization costs allows one to economize
on data collection. Our experiment suggested that col-
lecting a small number of estimates (in our data, approxi-
mately 25) in as many countries as is feasible minimizes
imputation error.
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OBJECTIVES: Patients with type 2 diabetes are known
to make increased use of health-care resources, but the
impact of specific macro and microvascular complica-
tions on costs is unclear. Here we use regression based
methods to estimate the immediate and long-term impact
of six diabetes-related complications on hospital costs,
using data from the UKPDS, a large (n  5102) and long-
term (median duration 10.3 years) clinical trial.
METHODS: Data on the occurrence and precise timing
of pre-defined diabetes-related complications, and on all
hospitalisations with associated specialties, lengths of
stay, and procedures, were collected routinely for all pa-
tients during the trial. Panel data regression analysis was
used to estimate the immediate impact (i.e. in the year
event occurred) and long-term impact (i.e. in each subse-
quent year) of the following six diabetes-related compli-
cations on hospital costs: fatal and non fatal myocardial
infarction (n  828); fatal and non-fatal stroke (n 
271); heart failure (n  166); angina (n  319); blindness
in one eye (n  166); amputation (n  67). Hospital
costs were calculated using national average specialty-
specific costs per inpatient day, expressed in 1999 £s UK.
RESULTS: All six diabetes-related complications had a
statistically significant impact on hospital costs. In the
year in which the complication occurred, diabetes-related
complications were associated with increased hospital
costs ranging from £995 for loss of sight in one eye to
£5478 for an amputation. In subsequent years the annual
magnitude of this effect ranged from 13% to 33% of the
costs in the initial year.
CONCLUSIONS: Regression analysis on a large and
well-validated, patient-specific data set yields plausible
empirically based estimates of the hospital cost conse-
quences of diabetes-related complications. These will be
of use to other economists and health service researchers,
particularly those interested in assessing the costs of dia-
betes and the cost-effectiveness of interventions within a
modeling framework.
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OBJECTIVES: To compare top down and bottom up
cost estimates of direct health-care costs for diabetes type
2 in the Netherlands.
METHODS: For the top down cost estimates we used
comprehensive Dutch national age and sex-specific cost
of illness estimates for diabetes and diseases related to di-
abetes complications. Costs for diabetes type 2 were sep-
arated by age (age 35 and older) and by prevalence rates
for types 1 and 2. The costs of complications were esti-
mated using costs and prevalence rates for cardiovascular
diseases, neuropathy, nephropathy and retinopathy, com-
bined with relative risks for these complications in pa-
tients with diabetes type 2. The bottom up costs were es-
timated using a sample of 1371 type 2 diabetes patients
for whom their GP reported the total medical consump-
tion related to diabetes and its complications during the
previous six months.
RESULTS: Total medical costs for diabetes type 2 in
1998 were Euro 567 mln according to the bottom up es-
timate versus Euro 519 mln for the top down estimate, or
less than 10 % difference in cost. The costs for in hospital
care, ambulatory care and equipment were very compa-
rable. The cost of medication was higher according to the
bottom up study. The bottom up study identified a larger
amount of cardiovascular and lipid lowering drugs. Both
costing methods show that complications, especially car-
diovascular, are responsible for a substantial portion of
total health-care costs.
CONCLUSIONS: For diabetes type 2 it was demon-
strated that using comprehensive top down disease costs
combined with sound epidemiological data on complica-
tions, can yield valid cost estimates that are quite compa-
rable with bottom up cost estimates.
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OBJECTIVE: To develop a model for predicting hospital
costs in patients with diabetes mellitus.
METHODS: We have previously shown that, in compar-
ison with standard cost models, better prediction can be
achieved with a two-part model that independently pre-
dicts risk of hospitalization and cost of hospitalization. In
this analysis we have developed a three-part model by
adding mortality to the original two-part model, because
patients who die do not necessarily incur hospital costs in
the year of death. Furthermore we have extended the
three-part model to an autoregression model. Age, gen-
der, any hospitalization in the last year, log-hospital costs
in the last year and log-mean costs over all previous years
were included in the model. A Bayesian forecasting
method was used to obtain a predictive distribution of
costs in the next year.
RESULTS: We identified 5672 type 2 diabetic patients in
the Tayside area and analyzed annual hospital costs be-
tween 1988 and 1995. The fitted three-part model showed
that increasing age was associated with increasing mor-
tality and with increasing costs per hospital episode.
However, age was not associated with the risk of hospi-
talization. Cost of hospitalization in previous years was
positively associated with risk of hospitalization (OR 
1.51/ln(mean costs), CI  1.48, 1.53) and mortality (OR 
1.22/ln(mean costs), CI  1.19,1.25). An example of
Bayesian cost forecasting showed that for female patients
aged 50 to 59, increasing hospital costs in the previous
year increased the probability of having a high-cost hos-
